These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 23601239)

  • 1. IGF-1R as an anti-cancer target--trials and tribulations.
    Chen HX; Sharon E
    Chin J Cancer; 2013 May; 32(5):242-52. PubMed ID: 23601239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
    van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
    Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we unlock the potential of IGF-1R inhibition in cancer therapy?
    King H; Aleksic T; Haluska P; Macaulay VM
    Cancer Treat Rev; 2014 Oct; 40(9):1096-105. PubMed ID: 25123819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
    Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
    Singh P; Alex JM; Bast F
    Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
    Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
    Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
    Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
    Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?
    Gombos A; Metzger-Filho O; Dal Lago L; Awada-Hussein A
    Invest New Drugs; 2012 Dec; 30(6):2433-42. PubMed ID: 22415797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
    Rieder S; Michalski CW; Friess H; Kleeff J
    Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
    Olmos D; Tan DS; Jones RL; Judson IR
    Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy of the insulin-like growth factor-1 receptor in cancer.
    Paz K; Hadari YR
    Comb Chem High Throughput Screen; 2008 Jan; 11(1):62-9. PubMed ID: 18220543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
    Hewish M; Chau I; Cunningham D
    Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):54-72. PubMed ID: 19149688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
    Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
    Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
    Buck E; Mulvihill M
    Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
    Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
    PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy.
    Zha J; Lackner MR
    Clin Cancer Res; 2010 May; 16(9):2512-7. PubMed ID: 20388853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.